# Teleflex Completes Enrollment in Study for Longer Freesolve Heart Scaffolds

- URL: https://stocks.freetheai.org/news/teleflex-completes-enrollment-in-study-for-longer-freesolve-heart-scaffolds-0a1052
- Published: 2026-10-12T10:30:00Z
- Category: company_news; sentiment: bullish; impact: low
- Symbols: [NYSE:TFX](https://stocks.freetheai.org/symbols/NYSE-TFX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Teleflex Incorporated (NYSE:TFX) completed patient enrollment in its BIOMAG-LL clinical trial, which tests longer versions of its Freesolve resorbable magnesium scaffold. The international trial focuses on evaluating 35 mm and 40 mm scaffold lengths to treat de novo coronary artery lesions up to 38 mm in length. Shares of Teleflex were trading up 0.75% at $125.10 following the update.

Long coronary artery lesions present procedural challenges in heart interventions, often requiring multiple permanent stents or overlapping devices. Longer resorbable scaffolds are designed to support blood vessels temporarily before dissolving, which can potentially reduce the need for permanent metallic implants, simplify treatment, and avoid excessive scaffold overlap in patients with diffuse coronary disease. Currently, the Freesolve scaffold is commercially available only in countries accepting the CE mark.

Researchers will track patients in the study at intervals up to 60 months, with the primary endpoint assessing the target lesion failure rate at 12 months. In addition, the 35 mm and 40 mm device sizes are being evaluated in the ongoing BIOMAG-III pivotal clinical trial in the United States and other international markets, where the device remains restricted to investigational use.

## Key points

- Teleflex Incorporated finished patient enrollment in the BIOMAG-LL clinical study for 35 mm and 40 mm Freesolve scaffolds.
- The trial tests the device in de novo coronary artery lesions up to 38 mm long, with a primary safety and effectiveness endpoint at 12 months.
- Longer resorbable magnesium scaffolds aim to treat extended vessel lesions with fewer implants and avoid long permanent stented segments.
- The 35 mm and 40 mm sizes are also being studied in the U.S. BIOMAG-III trial, where the product is currently an investigational device.

## Questions and answers

### What did Teleflex announce regarding the BIOMAG-LL study?

Teleflex completed patient enrollment in the BIOMAG-LL clinical trial, which evaluates 35 mm and 40 mm lengths of the Freesolve resorbable magnesium scaffold for treating coronary artery lesions up to 38 mm.

### Is the Freesolve resorbable magnesium scaffold approved in the United States?

No, the Freesolve resorbable magnesium scaffold is an investigational device in the United States. It is currently commercially available only in countries that recognize the CE mark.

### What is the main clinical endpoint for the BIOMAG-LL study?

The primary endpoint is the target lesion failure rate at 12 months, with overall clinical follow-up extending up to 60 months post-procedure.